ERBB2 and cancer: There was basically little impact on the final results of HER2 status for testing different blocks and interpreting different slides (random counting of at least 20 cancer cells in at least 2 invasive regions, according to the criteria) for a vast majority of cases without intratumoral heterogeneity.